Abstract：【Objective】To explore the predictive value of serum levels of carbohydrate antigen 125 (CA125),carcinoembryonic antigen (CEA),and human epididymal protein 4 (HE4) in the clinical prognosis of ovarian cancer patients.【Methods】A total of 159 ovarian cancer patients (ovarian cancer group) admitted to the Hanzhong Central Hospital from May 2020 to July 2022 were selected,and 138 healthy volunteers (health group) who underwent physical examinations at Hanzhong Central Hospital during the same period were selected as controls. Compare the serum levels of CA125,CEA,and HE4 between the two groups,and analyze the clinical outcomes of the ovarian cancer group after three courses of chemotherapy. We compared the clinical data of patients in the improvement group and the adverse outcome group,analyzed the influencing factors of clinical outcome,and the predictive value of serum CA125,CEA,and HE4 levels for clinical improvement in ovarian cancer patients.【Results】The serum levels of CA125,CEA,and HE4 in the ovarian cancer group were higher than those in the healthy group (P<0.05); The serum levels of CA125,CEA,and HE4 in the improvement group were lower than those in the adverse outcome group (P<0.05); The difference in the proportion of refractory ascites and lymph node metastasis between the improvement group and the adverse outcome group was statistically significant (P<0.05); Serum levels of CA125,CEA,HE4,and refractory ascites are all related factors that affect clinical improvement (P<0.05); The analysis results of the receiver operating characteristic (ROC) curve showed that the optimal cutoff points for predicting clinical improvement in ovarian cancer patients with serum CA125,CEA,and HE4 levels were 541.39 U/mL,4.96 ng/mL,and 230.79 pmol/L,respectively,with specificity of 71.21%,75.76%,and 77.27%. The area under the curve (AUC) was 0.750,0.709,and 0.782,respectively. The specificity and AUC predicted by the combination of the three were 96.97% and 0.820,respectively.【Conclusion】Serum levels of CA125,CEA,and HE4 in patients with clinical improvement of ovarian cancer are lower than those in patients with poor prognosis. Serum levels of CA125,CEA,and HE4 are all related factors that affect clinical improvement of ovarian cancer patients. Serum levels of CA125,CEA,and HE4 can be used as sensitive indicators to predict clinical prognosis of ovarian cancer,and the combined predictive value is higher.
常捷芳, 李娟. 血清CA125、CEA、HE4水平对卵巢癌患者临床转归的预测价值[J]. 医学临床研究, 2023, 40(9): 1292-1295.
CHANG Jiefang, LI Juan. The Predictive Value of Serum CA125,CEA,and HE4 Levels for Clinical Outcomes in Ovarian Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1292-1295.
[1] 任娟,闫丽明,史喜梅. miR-141-3p、miR-200a在卵巢癌患者外周血中的表达及其对化疗敏感性的预测价值[J].医学临床研究,2023,40(3):352-355. [2] 张静,黄普艳,杜丽娟. 卵巢癌患者的FOLR1、CA125水平变化及其临床意义研究[J].实验与检验医学,2019,37(3):361-363. [3] LIN Y H,WU C H,FU H C,et al. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer[J].Cancer Biomark,2020,28(3):285-292. [4] YANG W L,LU Z,GUO J,et al. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer[J].Cancer,2020,126(4):725-736. [5] 周琦,吴小华,刘继红,等. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749. [6] 钱素敏. 妇科恶性肿瘤[M]. 上海:科学技术文献出版社,2013:84-86. [7] LEE J M,MINASIAN L,KOHN E C. New strategies in ovarian cancer treatment[J].Cancer,2019,125(Suppl 24):4623-4629. [8] NOWAK M,KLINK M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer[J].Cells,2020,9(5):1299-1304. [9] BONIFÁCIO V D B. Ovarian cancer biomarkers: moving forward in early detection[J].Adv Exp Med Biol,2020,19(4):355-363. [10] 齐燕蓉,丁亚. 肿瘤标志物癌胚抗原和糖类抗原125检测在卵巢癌诊断与治疗中的意义[J].中国医刊,2020,55(2):167-170. [11] LI M,TAN J,ZHANG Y,et al. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer[J].Abdom Radiol (NY),2021,46(6):2367-2375. [12] DOCHEZ V,CAILLON H,VAUCEL E,et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125,HE4,RMI and ROMA,a review[J].J Ovarian Res,2019,12(1):28-36. [13] 刘坤,李英,齐红双,等. 血清CEA、HE4、CA199、CA153、CA125水平联合检测在妇科恶性肿瘤诊断中的临床意义[J].实验与检验医学,2020,38(2):326-328.
2023, Vol. 40 
